Boris Kashemirov

Dr. Boris Kashemirov

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LPLarryn W. Peterson
Larryn W. Peterson
MSMonica Sala-Rabanal
Monica Sala-Rabanal
IKIvan S. Krylov
Ivan S. Krylov
MSMichaela Serpi
Michaela Serpi
BKBoris Kashemirov
Boris Kashemirov
Charles McKennaCharles McKenna
Charles McKenna

26 July 2023 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
MJMichaela R. Jacobs
Michaela R. Jacobs
JOJennifer E. Olivero
Jennifer E. Olivero
HCHyun Ok Choi
Hyun Ok Choi
CLChun-Peng Liao
Chun-Peng Liao
BKBoris Kashemirov
Boris Kashemirov
Charles McKennaCharles McKenna
Charles McKenna
Monoamine oxidases (MAOA/MAOB) are enzymes known for their role in neurotransmitter regulation in the central nervous system (CNS). Irreversible and non-selective MAO inhibitors (MAOi's) were the first class of antidepressants, thus subsequent work on drugs such as the selective MAOA inhibitor clorgyline has focussed on selectivity and increased CNS penetration. MAOA is highly expressed in high grade and metastatic prostate cancer with a proposed effect on prostate cancer growth, recurrence, and drug resistance. A Phase II Clinical Trial has demonstrated the therapeutic effects of the irreversible nonselective MAOi phenelzine for prostate cancer. However, neurologic adverse effects led to early withdrawal in 25% of the enrolled patient-population. In this work, we revised the clorgyline scaffold with the goal of decreasing CNS penetration to minimize CNS-related side effects while retaining or enhancing MAOA inhibition potency and selectivity. Using the known co-crystal structure of clorgyline bound with FAD co-factor in the hMAOA active site as a reference, we designed and synthesized a series of compounds predicted to have lower CNS penetration (logBB). All synthesized derivatives displayed favorable drug-like characteristics such as predicted Caco-2 permeability and human oral absorption, and exhibited highly selective hMAOA binding interactions. Introduction of an HBD group (NH2 or OH) at position 5 of the phenyl ring clorgyline resulted in 3x more potent hMAOA inhibition with equivalent or better hMAOB selectivity, and similar prostate cancer cell cytotoxicity. In contrast, introduction of larger substituents at this position or at the terminal amine significantly reduced the hMAOA inhibition potency, attributed in part to a steric clash within the binding pocket of the MAOA active site. Replacement of the N-methyl group by a more polar, but larger 2-hydroxyethyl group did not enhance potency. However, introduction of a polar 2-hydroxy in the propyl chain retained the highly selective MAOA inhibition and cancer cell cytotoxicity of clorgyline while reducing its CNS score from 2 to 0. We believe that these results identify a new class of peripherally directed MAOIs that may allow safer therapeutic targeting of MAOA for a variety of anti-cancer and anti-inflammatory indications.

19 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KPKatherin Patsch
Katherin Patsch
CLChao Liu
Chao Liu
Grzegorz ZapotocznyGrzegorz Zapotoczny
Grzegorz Zapotoczny
YSYuanye Sun
Yuanye Sun
HSHarish Sura
Harish Sura
DRDaniel Ruderman
Daniel Ruderman
Small molecules that target the androgen receptor (AR) are the mainstay of therapy for lethal castration-resistant prostate cancer (CRPC), yet existing drugs lose their efficacy during continued treatment. This evolution of resistance is due to heterogenous mechanisms which include AR mutations causing the identical drug to activate instead of inhibit the receptor. Understanding in molecular detail the paradoxical phenomenon wherein an AR antagonist is transformed into an agonist by structural mutations in the target receptor is thus of paramount importance. Herein, we describe a reciprocal paradox: opposing antagonist and agonist AR regulation determined uniquely by enantiomeric forms of the same drug structure. The antiandrogen BMS-641988, which has ( R )-chirality at C-5 encompasses a previously uncharacterized ( S )-stereoisomer that is, surprisingly, a potent agonist of AR, as demonstrated by transcriptional assays supported by cell imaging studies. This duality was reproduced in a series of novel compounds derived from the BMS-641988 scaffold. Coupled with in silico modeling studies, the results inform an AR model that explains the switch from potent antagonist to high-affinity agonist in terms of C-5 substituent steric interactions with helix 12 of the ligand binding site. They imply strategies to overcome AR drug resistance and demonstrate that insufficient enantiopurity in this class of AR antagonist can confound efforts to correlate structure with function.

15 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
DMDana Mustafa
Dana Mustafa
JOJustin Overhulse
Justin Overhulse
BKBoris Kashemirov
Boris Kashemirov
Charles McKennaCharles McKenna
Charles McKenna
Phosphonic acids represent one of the most important categories of organophosphorus compounds, with myriad examples found in chemical biology, medicine, materials, and other domains. Phosphonic acids are rapidly and conveniently prepared from their simple dialkyl esters by silyldealkylation with bromotrimethylsilane (BTMS), followed by desilylation upon contact with water or methanol. Introduced originally by McKenna, the BTMS route to phosphonic acids has long been a favored method due to its convenience, high yields, very mild conditions, and chemoselectivity. We systematically investigated microwave irradiation as a means to accelerate the BTMS silyldealkylations (MW-BTMS) of a series of dialkyl methylphosphonates with respect to solvent polarity (ACN, dioxane, neat BTMS, DMF, and sulfolane), alkyl group (Me, Et, and iPr), electron-withdrawing P-substitution, and phosphonate–carboxylate triester chemoselectivity. Control reactions were performed using conventional heating. We also applied MW-BTMS to the preparation of three acyclic nucleoside phosphonates (ANPs, an important class of antiviral and anticancer drugs), which were reported to undergo partial nucleoside degradation under MW hydrolysis with HCl at 130–140 °C (MW-HCl, a proposed alternative to BTMS). In all cases, MW-BTMS dramatically accelerated quantitative silyldealkylation compared to BTMS with conventional heating and was highly chemoselective, confirming it to be an important enhancement of the conventional BTMS method with significant advantages over the MW-HCl method.

9 May 2011 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
KBKatarzyna M. Błażewska
Katarzyna M. Błażewska
RHRalf Haiges
Ralf Haiges
BKBoris Kashemirov
Boris Kashemirov
FEFrank H Ebetino
Frank H Ebetino
Charles McKennaCharles McKenna
Charles McKenna
Under certain conditions, the phosphonocarboxylate analogue (3) of the bisphosphonate drug minodronate (4) in contact with borosilicate glassware reversibly forms an isolable dimer complex of boron, as revealed by the X-ray crystallographic structure of the (R,R/S,S) complex and supported by NMR and HRMS data.

1 March 2008 in Bone
Verified
Journal Article
Closed access
ARAnke J. Roelofs
Anke J. Roelofs
FCFraser P. Coxon
Fraser P. Coxon
FEFrank H Ebetino
Frank H Ebetino
JBJoy F. Bala
Joy F. Bala
BKBoris Kashemirov
Boris Kashemirov
MRMichael J. Rogers
Michael J. Rogers